A phase Ib trial (NCT03014076) indicated that GP2 vaccine with GM-CSF and trastuzumab was obligated to trigger interferon-γ secretion (144 vs 46 secreting spots as the baseline, p = 0.13) indicative of immunologic responses, and as well safe in 17 disease-free, HER2/neu-high-expressing, HLA-A2/A3 + breast cancer patients (Clifton et al. 2017). The gene discussed is ERBB2; the disease is breast carcinoma.